Results | Latest & Breaking News on Results | Photos, Videos, Breaking Stories and Articles on Results

you are here: Home News

Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
Cipla set to launch key drugs Abraxane and Advair in FY26
Multiple near-term challenges may hijack Cipla's growth trajectory
Cipla's strong US pipeline, steady Q4 earnings and hopes of easing regulatory snags drive bullishness
Cipla Q4 results preview: Revenue boost likely from strong US sales, net profit to jump from low base
Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities
Cipla Q1 PAT seen up 15.6% YoY to Rs 793.7 cr: Nirmal Bang
Cipla Q4 preview: Robust domestic traction, gRevlimid sales likely to give earnings a big boost
Cipla Q4 PAT seen up 58% YoY to Rs 6,485 cr: Nirmal Bang
Cipla Q3 preview | Consolidated net profit likely to rise 22% YoY
Cipla Q3 PAT seen up 33.1% YoY to Rs 9,699 cr: Nirmal Bang
Cipla Q2 preview | Consolidated net profit likely to rise 9% YoY
Cipla Q1 Preview | Profit may decline 10% YoY on flat revenue
Cipla Q1 PAT may dip 23.2% YoY to Rs 645 cr: Prabhudas Lilladher
Cipla Results Preview | Consolidated net profit may rise 47% on India ops
Cipla Q4 PAT seen up 27.6% YoY to Rs 527.6 cr: Prabhudas Lilladher
Cipla Q3 PAT may dip 6.4% YoY to Rs 700.3 cr: Prabhudas Lilladher
Cipla Q2 PAT seen up 20.3% YoY to Rs 793.4 cr: Prabhudas Lilladher
Cipla Q1 PAT seen up 10.9% YoY to Rs 640.7 cr: KRChoksey
Cipla Q1 PAT may dip 7.5% YoY to Rs 534.3 cr: ICICI Direct
Cipla Q4 PAT seen up 147.8% YoY to Rs. 609 cr: Sharekhan
Cipla Q3 PAT seen up 74.3% YoY to Rs. 612 cr: Yash Securities
Cipla Q3 PAT seen up 77.2% YoY to Rs. 351 cr: Prabhudas Lilladher
Cipla Q3 PAT seen up 73.2% YoY to Rs. 608.1 cr: ICICI Direct
Cipla Q4 profit, revenue could decline due to high-base effect

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities

Cipla set to launch key drugs Abraxane and Advair in FY26

Multiple near-term challenges may hijack Cipla's growth trajectory

Cipla's strong US pipeline, steady Q4 earnings and hopes of easing regulatory snags drive bullishness

Cipla Q4 results preview: Revenue boost likely from strong US sales, net profit to jump from low base

Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities

Cipla Q1 PAT seen up 15.6% YoY to Rs 793.7 cr: Nirmal Bang

Cipla Q4 preview: Robust domestic traction, gRevlimid sales likely to give earnings a big boost

Cipla Q4 PAT seen up 58% YoY to Rs 6,485 cr: Nirmal Bang

Cipla Q3 preview | Consolidated net profit likely to rise 22% YoY

Cipla Q3 PAT seen up 33.1% YoY to Rs 9,699 cr: Nirmal Bang

Cipla Q2 preview | Consolidated net profit likely to rise 9% YoY

Cipla Q1 Preview | Profit may decline 10% YoY on flat revenue

Cipla Q1 PAT may dip 23.2% YoY to Rs 645 cr: Prabhudas Lilladher

Cipla Results Preview | Consolidated net profit may rise 47% on India ops

Cipla Q4 PAT seen up 27.6% YoY to Rs 527.6 cr: Prabhudas Lilladher

Cipla Q3 PAT may dip 6.4% YoY to Rs 700.3 cr: Prabhudas Lilladher

Cipla Q2 PAT seen up 20.3% YoY to Rs 793.4 cr: Prabhudas Lilladher

Cipla Q1 PAT seen up 10.9% YoY to Rs 640.7 cr: KRChoksey

Cipla Q1 PAT may dip 7.5% YoY to Rs 534.3 cr: ICICI Direct

Cipla Q4 PAT seen up 147.8% YoY to Rs. 609 cr: Sharekhan

Cipla Q3 PAT seen up 74.3% YoY to Rs. 612 cr: Yash Securities

Cipla Q3 PAT seen up 77.2% YoY to Rs. 351 cr: Prabhudas Lilladher

Cipla Q3 PAT seen up 73.2% YoY to Rs. 608.1 cr: ICICI Direct

Cipla Q4 profit, revenue could decline due to high-base effect